NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
40 trialsNCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT07460206 2026-03-10
PRELUDE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT06860386 2026-03-06
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Suspended
NCT06661720 2026-03-04
STRIKE
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT02432963 2026-01-28
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05327686 2026-01-14
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT07187778 2026-01-05
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05363631 2025-12-10
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
University of Iowa
Phase 1/2 Active not recruiting
NCT03260504 2025-12-08
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
Phase 1 Terminated
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT07223424 2025-11-10
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT06005818 2025-10-21
MRD GATE RCC
University of Alabama at Birmingham
Phase 2 Recruiting
NCT07037004 2025-09-23
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT06302569 2025-09-09
REPRINT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Recruiting
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT02318771 2025-05-15
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Thomas Jefferson University
Phase 1 Completed
NCT05969496 2025-04-04
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT03149822 2025-03-13
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 1/2 Completed
NCT05733715 2025-03-03
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting
NCT04393350 2025-02-26
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Phase 2 Active not recruiting
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT05485896 2024-09-19
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Completed
NCT05024318 2024-05-16
NAPSTER
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT04187872 2023-12-27
TORCH
University of Florida
Phase 1 Terminated
NCT03229278 2023-12-06
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT06146777 2023-11-29
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT02855203 2023-08-03
RAPPORT
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Completed
NCT03280667 2023-03-29
KEYPAD
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT04913025 2022-09-21
REFINE
University College, London
Phase 2 Unknown
NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
NCT02599779 2021-09-01
OZM-065
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT04995016 2021-08-06
PANDORA
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03189186 2021-04-05
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
University of California, Irvine
Phase 1 Withdrawn
NCT03111901 2019-07-12
UVA-AM-002
University of Virginia
Phase 1/2 Withdrawn